Skip to main content
Top
Published in: Drugs 19/2004

01-10-2004 | Review Article

Antiepileptic Drugs in the Treatment of Anxiety Disorders

Role in Therapy

Authors: Dr Michael Van Ameringen, Catherine Mancini, Beth Pipe, Mark Bennett

Published in: Drugs | Issue 19/2004

Login to get access

Abstract

Pharmacotherapy for anxiety disorders is an active area of research. A variety of drug groups have been shown to be effective in treating many of the anxiety disorders, with selective serotonin reuptake inhibitors (SSRIs) being considered first-line agents for virtually all anxiety disorders. There is a clinical need for alternative drug treatments, as many patients do not achieve a complete response and experience significant adverse effects. The successful use of antiepileptic drugs in mood disorders has led clinicians and researchers to investigate their potential efficacy in other psychiatric disorders, particularly in anxiety disorders.
There have been a number of investigations conducted in the form of case reports, case series and open-label trials, suggesting the potential usefulness of antiepileptic drug treatment in a variety of anxiety disorders. More reliable evidence for the use of antiepileptic drugs in anxiety disorders can be gleaned from recent placebo-controlled trials. Thus far, the strongest placebo-controlled evidence has demonstrated the efficacy of pregabalin in treating social phobia and generalised anxiety disorder, while smaller or less robust controlled trials have suggested the potential efficacy of gabapentin in social phobia, lamotrigine in post-traumatic stress disorder, and valproic acid in panic disorder.
Antiepileptic drugs may have a place in the treatment of anxiety disorders; however, further investigation is warranted to determine in what circumstances they should be used as monotherapy or as augmenting agents in individuals who are partially or non-responsive to conventional therapy.
Literature
1.
go back to reference van Steveninck AL, Wallnofer AE, Schoemaker RC, et al. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 1997; 44(3): 267–75PubMed van Steveninck AL, Wallnofer AE, Schoemaker RC, et al. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 1997; 44(3): 267–75PubMed
2.
go back to reference Cowley DS, Roy-Bryne PP, Radant A, et al. Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 1995; 12(2): 147–57PubMed Cowley DS, Roy-Bryne PP, Radant A, et al. Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 1995; 12(2): 147–57PubMed
3.
go back to reference Rapport DJ, Calabrese JR. Tolerance to fluoxetine [letter]. J Clin Psychpharmacol 1993; 13(5): 361 Rapport DJ, Calabrese JR. Tolerance to fluoxetine [letter]. J Clin Psychpharmacol 1993; 13(5): 361
4.
go back to reference Pope Jr HG, McElroy SL, Keck Jr PE, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48(1): 62–8PubMed Pope Jr HG, McElroy SL, Keck Jr PE, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48(1): 62–8PubMed
5.
go back to reference Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987; 48(3): 89–93PubMed Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987; 48(3): 89–93PubMed
6.
go back to reference Quirk GJ, Gehlert DR. Inhibition of the amygdala: key to pathological states? Ann N Y Acad Sci 2003; 985: 263–72PubMed Quirk GJ, Gehlert DR. Inhibition of the amygdala: key to pathological states? Ann N Y Acad Sci 2003; 985: 263–72PubMed
7.
go back to reference LeDoux JE. The emotional brain. N w York: Simon & Schuster, 1996 LeDoux JE. The emotional brain. N w York: Simon & Schuster, 1996
8.
go back to reference Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry 2003; 64 Suppl. 3: 21–7PubMed Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry 2003; 64 Suppl. 3: 21–7PubMed
9.
go back to reference Goddard AW, Mason GF, Almai A, et al. Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry 2001; 58: 556–61PubMed Goddard AW, Mason GF, Almai A, et al. Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry 2001; 58: 556–61PubMed
10.
go back to reference Smith TA. Type A gamma-aminobutryric acid (GABAA) receptors subunits and benzodiazepines binding site sensitivity. Nature 1978; 274: 383–5 Smith TA. Type A gamma-aminobutryric acid (GABAA) receptors subunits and benzodiazepines binding site sensitivity. Nature 1978; 274: 383–5
11.
go back to reference Rosenberg DR, MacMaster F, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000; 39(9): 1096–103PubMed Rosenberg DR, MacMaster F, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000; 39(9): 1096–103PubMed
12.
go back to reference Mathew SJ, Coplan JD, Gorman JM. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 2001; 158(10): 1558–67PubMed Mathew SJ, Coplan JD, Gorman JM. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 2001; 158(10): 1558–67PubMed
13.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994
14.
go back to reference Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine in the treatment of social phobia: a double-blind, placebo-controlled study. Am J Psychiatry 1999; 156: 756–60PubMed Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine in the treatment of social phobia: a double-blind, placebo-controlled study. Am J Psychiatry 1999; 156: 756–60PubMed
15.
go back to reference Stein MB, Liebowitz M, Lydiard RB, et al. Paroxetine in the treatment of generalized social phobia (social anxiety disorder). JAMA 1998; 280: 708–13PubMed Stein MB, Liebowitz M, Lydiard RB, et al. Paroxetine in the treatment of generalized social phobia (social anxiety disorder). JAMA 1998; 280: 708–13PubMed
16.
go back to reference Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 275–81PubMed Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 275–81PubMed
17.
go back to reference Liebowitz MR, Mangano R. Comparison of venlafaxine extended-release (ER) and paroxetine in the short-term treatment of SAD [poster]. 41st annual meeting of the American College of Neuropsychopharmacology (ACNP); 2002 Dec 8–12; San Juan, Puerto Rico Liebowitz MR, Mangano R. Comparison of venlafaxine extended-release (ER) and paroxetine in the short-term treatment of SAD [poster]. 41st annual meeting of the American College of Neuropsychopharmacology (ACNP); 2002 Dec 8–12; San Juan, Puerto Rico
18.
go back to reference Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioural and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991; 48: 938–45PubMed Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioural and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991; 48: 938–45PubMed
19.
go back to reference Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo controlled comparison. Arch Gen Psychiatry 1992; 49(4): 290–300PubMed Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo controlled comparison. Arch Gen Psychiatry 1992; 49(4): 290–300PubMed
20.
go back to reference Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch Gen Psychiatry 1998; 55: 1133–41PubMed Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch Gen Psychiatry 1998; 55: 1133–41PubMed
21.
go back to reference Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. Acta Psychiatr Scand 1995; 92: 251–358 Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. Acta Psychiatr Scand 1995; 92: 251–358
22.
go back to reference Schneier FR, Goetz D, Campeas R, et al. Placebo controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172: 70–7PubMed Schneier FR, Goetz D, Campeas R, et al. Placebo controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172: 70–7PubMed
23.
go back to reference Biton V, Edwards KR, Montouis GD, et al. Topiramate titration and tolerability. Ann Pharmacother 2001; 35: 173–9PubMed Biton V, Edwards KR, Montouis GD, et al. Topiramate titration and tolerability. Ann Pharmacother 2001; 35: 173–9PubMed
24.
go back to reference Van Ameringen M, Mancini C, Pipe B, et al. An open-trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. In press Van Ameringen M, Mancini C, Pipe B, et al. An open-trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. In press
25.
go back to reference Stein MB, Pollack MH, Mangano R. Long-term treatment of generalized SAD with venlafaxine extended release [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco Stein MB, Pollack MH, Mangano R. Long-term treatment of generalized SAD with venlafaxine extended release [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco
26.
go back to reference Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19(4): 341–8PubMed Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19(4): 341–8PubMed
27.
go back to reference Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001; 132: 1–4PubMed Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001; 132: 1–4PubMed
28.
go back to reference Feltner DE, Davidson JRT, Pollack MH, et al. A placebo-controlled, double-blind study of pregabalin treatment of social anxiety disorder: Outcome and predictors of response [abstract]. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10–14; San Juan, Puerto Rico Feltner DE, Davidson JRT, Pollack MH, et al. A placebo-controlled, double-blind study of pregabalin treatment of social anxiety disorder: Outcome and predictors of response [abstract]. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10–14; San Juan, Puerto Rico
29.
go back to reference Nardi AE, Mendolwicz M, Versiani FM. Valproic acid in social phobia: an open trial [abstract]. Biol Psychiatry 1997; 42: 118S Nardi AE, Mendolwicz M, Versiani FM. Valproic acid in social phobia: an open trial [abstract]. Biol Psychiatry 1997; 42: 118S
30.
go back to reference Kinrys G, Pollack MH, Simon NM, et al. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003; 18: 169–72PubMed Kinrys G, Pollack MH, Simon NM, et al. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003; 18: 169–72PubMed
31.
go back to reference Fink-Jensen A, Suzdak PD, Swedberg MD, et al. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increased extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992; 220: 197–201PubMed Fink-Jensen A, Suzdak PD, Swedberg MD, et al. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increased extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992; 220: 197–201PubMed
32.
go back to reference Borden LA, Murali Dhar TG, Smith KE, et al. Tiagabine, SK &F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994; 269(2): 219–24PubMed Borden LA, Murali Dhar TG, Smith KE, et al. Tiagabine, SK &F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994; 269(2): 219–24PubMed
33.
go back to reference Papp LA, Ninan PT. Tiagabine for the treatment of social anxiety disorder [abstract]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York Papp LA, Ninan PT. Tiagabine for the treatment of social anxiety disorder [abstract]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York
34.
go back to reference Kinrys G, Sodani F, Hsu D, et al. Adjunctive tiagabine for treatment refractory social anxiety disorder [poster]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York Kinrys G, Sodani F, Hsu D, et al. Adjunctive tiagabine for treatment refractory social anxiety disorder [poster]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York
35.
go back to reference Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101(26): 9861–6PubMed Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101(26): 9861–6PubMed
36.
go back to reference Simon NM, Worthington JJ, Doyle AC, et al. Levetiracetam for treatment of social anxiety disorder [poster]. Anxiety Disorders Association of America’s 23rd National Conference; 2004 Mar 16–20; Miami Simon NM, Worthington JJ, Doyle AC, et al. Levetiracetam for treatment of social anxiety disorder [poster]. Anxiety Disorders Association of America’s 23rd National Conference; 2004 Mar 16–20; Miami
37.
go back to reference Ballenger JA, Davidson JRT, Lecrubier Y, et al. Consensus statement on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 2000; 61 Suppl. 5: 60–6PubMed Ballenger JA, Davidson JRT, Lecrubier Y, et al. Consensus statement on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 2000; 61 Suppl. 5: 60–6PubMed
38.
go back to reference Connor KM, Sutherland SM, Tupler LA, et al. Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. Br J Psychiatry 1999; 175: 17–22PubMed Connor KM, Sutherland SM, Tupler LA, et al. Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. Br J Psychiatry 1999; 175: 17–22PubMed
39.
go back to reference van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55: 517–22PubMed van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55: 517–22PubMed
40.
go back to reference Davidson JR, Rothbaum BO, van der Kolk BA, et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001 May; 58(5): 485–92PubMed Davidson JR, Rothbaum BO, van der Kolk BA, et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001 May; 58(5): 485–92PubMed
41.
go back to reference Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible dosage trial. J Clin Psychiatry 2001; 62(11): 860–8PubMed Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible dosage trial. J Clin Psychiatry 2001; 62(11): 860–8PubMed
42.
go back to reference Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158(12): 1982–8PubMed Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158(12): 1982–8PubMed
43.
go back to reference Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991; 179(6): 366–70PubMed Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991; 179(6): 366–70PubMed
44.
go back to reference Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline or placebo. Arch Gen Psychiatry 1990; 47(3): 259–66PubMed Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline or placebo. Arch Gen Psychiatry 1990; 47(3): 259–66PubMed
45.
go back to reference Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60(2): 79–88 Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60(2): 79–88
46.
go back to reference Hertzberg MA, Butterfield MI, Fledman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1997; 45(9): 1226–9 Hertzberg MA, Butterfield MI, Fledman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1997; 45(9): 1226–9
47.
go back to reference Berlant J, Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002; 63(1): 15–20PubMed Berlant J, Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002; 63(1): 15–20PubMed
48.
go back to reference Chengappa KN, Rathore D, Levine J, et al. Topiramate as addon treatment for patients with bipolar mania. Bipolar Disord 2001; 3(5): 215–32PubMed Chengappa KN, Rathore D, Levine J, et al. Topiramate as addon treatment for patients with bipolar mania. Bipolar Disord 2001; 3(5): 215–32PubMed
49.
go back to reference Brannon N, Labbate L, Huber M. Gabapentin treatment for posttraumatic stress disorder [letter]. Can J Psychiatry 2000; 45: 84PubMed Brannon N, Labbate L, Huber M. Gabapentin treatment for posttraumatic stress disorder [letter]. Can J Psychiatry 2000; 45: 84PubMed
50.
go back to reference Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13(3): 141–6PubMed Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13(3): 141–6PubMed
51.
go back to reference Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder [letter]. Am J Psychiatry 1991; 148(8): 1086–7PubMed Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder [letter]. Am J Psychiatry 1991; 148(8): 1086–7PubMed
52.
go back to reference Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; 52(9): 361–4PubMed Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; 52(9): 361–4PubMed
53.
go back to reference Petty F, Davis LL, Nugent AL, et al. Valproate therapy for chronic, combat-induced posttraumatic stress disorder [letter]. J Clin Psychopharmol 2002; 22(1): 100–2 Petty F, Davis LL, Nugent AL, et al. Valproate therapy for chronic, combat-induced posttraumatic stress disorder [letter]. J Clin Psychopharmol 2002; 22(1): 100–2
54.
go back to reference Otte C, Wiedemann K, Yassouridis A, et al. Valproate monotherapy in the treatment of civilian patients with noncombat-related posttraumatic stress disorder: an open-label study [letter]. J Clin Psychopharmacol 2004; 24(1): 106–8PubMed Otte C, Wiedemann K, Yassouridis A, et al. Valproate monotherapy in the treatment of civilian patients with noncombat-related posttraumatic stress disorder: an open-label study [letter]. J Clin Psychopharmacol 2004; 24(1): 106–8PubMed
55.
go back to reference Lara ME. Tiagabine for augmentation of antidepressant treatment of post-traumatic stress disorder [poster]. 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21–24; Austin Lara ME. Tiagabine for augmentation of antidepressant treatment of post-traumatic stress disorder [poster]. 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21–24; Austin
56.
go back to reference Berigan T. Treatment of posttraumatic stress disorder with tiagabine [letter]. Can J Psychiatry 2002; 47(8): 788PubMed Berigan T. Treatment of posttraumatic stress disorder with tiagabine [letter]. Can J Psychiatry 2002; 47(8): 788PubMed
57.
go back to reference Davidson J, Weisler R, Connor K, et al. Tiagabine for posttraumatic stress disorder: a placebo-controlled trial [poster]. 24th Annual Conference of the Anxiety Disorders Association of America; 2004 Mar 11–14; Miami Davidson J, Weisler R, Connor K, et al. Tiagabine for posttraumatic stress disorder: a placebo-controlled trial [poster]. 24th Annual Conference of the Anxiety Disorders Association of America; 2004 Mar 11–14; Miami
58.
go back to reference Lipper S, Davidson JRT, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; 27(12): 849–54PubMed Lipper S, Davidson JRT, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; 27(12): 849–54PubMed
59.
go back to reference Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry 1988; 23: 642–4PubMed Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry 1988; 23: 642–4PubMed
60.
go back to reference Looff D, Grimely P, Kuller F, et al. Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry 1995; 34(6): 703–4PubMed Looff D, Grimely P, Kuller F, et al. Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry 1995; 34(6): 703–4PubMed
61.
go back to reference Macleod AD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol 1996; 16(2): 190–1PubMed Macleod AD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol 1996; 16(2): 190–1PubMed
62.
go back to reference Berigan T. Oxcarbazepine treatment of posttraumatic stress disorder [letter]. Can J Psychiatry 2002; 47(10): 973–4PubMed Berigan T. Oxcarbazepine treatment of posttraumatic stress disorder [letter]. Can J Psychiatry 2002; 47(10): 973–4PubMed
63.
go back to reference Andersch S, Rosenberg NK, Kullingsjo H, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand 1991; 365: 18–27 Andersch S, Rosenberg NK, Kullingsjo H, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand 1991; 365: 18–27
64.
go back to reference Modgh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251–61 Modgh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251–61
65.
go back to reference Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37(1): 51–9PubMed Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37(1): 51–9PubMed
66.
go back to reference Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52: 69–76PubMed Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52: 69–76PubMed
67.
go back to reference Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed-dose study of alprazolam 2mg, alprazolam 6mg, and placebo in panic disorder. J Clin Psychopharmocol 1992; 12: 96–103 Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed-dose study of alprazolam 2mg, alprazolam 6mg, and placebo in panic disorder. J Clin Psychopharmocol 1992; 12: 96–103
68.
go back to reference Wade AG, Lepola U, Koponon HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549–53PubMed Wade AG, Lepola U, Koponon HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549–53PubMed
69.
go back to reference Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36–42PubMed Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36–42PubMed
70.
go back to reference Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998; 173: 54–60PubMed Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998; 173: 54–60PubMed
71.
go back to reference Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001; 103(1): 1–14PubMed Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001; 103(1): 1–14PubMed
72.
go back to reference Michelson D, Allgulander C, Dantendorfer K, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomized, placebo-controlled trial. Br J Psychiatry 2001; 179: 514–8PubMed Michelson D, Allgulander C, Dantendorfer K, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomized, placebo-controlled trial. Br J Psychiatry 2001; 179: 514–8PubMed
73.
go back to reference Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders [letter]. Am J Psychiatry 1998; 155(7): 992–3PubMed Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders [letter]. Am J Psychiatry 1998; 155(7): 992–3PubMed
74.
go back to reference Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20(4): 467–71PubMed Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20(4): 467–71PubMed
75.
go back to reference Brady KT, Sonne S, Lydiard RB. Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients [letter]. J Clin Psychopharmol 1994; 14(1): 81–2 Brady KT, Sonne S, Lydiard RB. Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients [letter]. J Clin Psychopharmol 1994; 14(1): 81–2
76.
go back to reference Roberts JM, Malcolm R, Santos AB. Treatment of panic disorder and comorbid substance abuse with divalproex sodium [letter]. Am J Psychiatry 1994; 151(10): 1521PubMed Roberts JM, Malcolm R, Santos AB. Treatment of panic disorder and comorbid substance abuse with divalproex sodium [letter]. Am J Psychiatry 1994; 151(10): 1521PubMed
77.
go back to reference McElroy S, Keck PE, Lawerence JM. Treatment of panic disorder and benzodiazepine withdrawal with valproate [letter]. J Neuropyschiatry Clin Neurosci 1991; 3(2): 232–3 McElroy S, Keck PE, Lawerence JM. Treatment of panic disorder and benzodiazepine withdrawal with valproate [letter]. J Neuropyschiatry Clin Neurosci 1991; 3(2): 232–3
78.
go back to reference Marazziti D, Cassano G. Valproic acid for panic disorder associated with multiple sclerosis [letter]. Am J Psychiatry 1996; 153(6): 842–3PubMed Marazziti D, Cassano G. Valproic acid for panic disorder associated with multiple sclerosis [letter]. Am J Psychiatry 1996; 153(6): 842–3PubMed
79.
go back to reference Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992; 17(2): 78–80PubMed Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992; 17(2): 78–80PubMed
80.
go back to reference Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990; 35: 248–50PubMed Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990; 35: 248–50PubMed
81.
go back to reference Woodman CL, Noyles R. Panic disorder: treatment with valproate. J Clin Psychiatry 1994; 55(4): 134–6PubMed Woodman CL, Noyles R. Panic disorder: treatment with valproate. J Clin Psychiatry 1994; 55(4): 134–6PubMed
82.
go back to reference Keck PE, Talyor VE, Tugrul KC, et al. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33: 542–6PubMed Keck PE, Talyor VE, Tugrul KC, et al. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33: 542–6PubMed
83.
go back to reference Baetz M, Bowen R. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998; 43(1): 73–7PubMed Baetz M, Bowen R. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998; 43(1): 73–7PubMed
84.
go back to reference Lum M, Fontaine R, Elie R, et al. Divalproex sodium’s antipanic effect in panic disorder: a placebo-controlled study [abstract]. Biol Psychiatry 1990; 27: 164A Lum M, Fontaine R, Elie R, et al. Divalproex sodium’s antipanic effect in panic disorder: a placebo-controlled study [abstract]. Biol Psychiatry 1990; 27: 164A
85.
go back to reference Gruener D. Tiagabine as an augmenting agent for the treatment of anxiety [poster]. 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21–24; Austin Gruener D. Tiagabine as an augmenting agent for the treatment of anxiety [poster]. 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21–24; Austin
86.
go back to reference Zwanzger P, Baghai TC, Schule C, et al. Tiagabine improves panic and agoraphobia in panic disorder patients [letter]. J Clin Psychiatry 2001; 62(8): 656–7PubMed Zwanzger P, Baghai TC, Schule C, et al. Tiagabine improves panic and agoraphobia in panic disorder patients [letter]. J Clin Psychiatry 2001; 62(8): 656–7PubMed
87.
go back to reference Zwanger P, Eser D, Padberg F, et al. Effects of tiagabine treatment on cholecystokin-tetrapeptide (CCK-4) induced anxiety in healthy volunteers [abstact P.4.W.064]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S215 Zwanger P, Eser D, Padberg F, et al. Effects of tiagabine treatment on cholecystokin-tetrapeptide (CCK-4) induced anxiety in healthy volunteers [abstact P.4.W.064]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S215
88.
go back to reference Lawlor BA. Carbamazepine, alprazolam withdrawal, and panic disorder. Am J Psychiatry 1987; 144(2): 265–6PubMed Lawlor BA. Carbamazepine, alprazolam withdrawal, and panic disorder. Am J Psychiatry 1987; 144(2): 265–6PubMed
89.
go back to reference Tondo L, Burrai C, Scamonatti L, et al. Carbamazepine in panic disorder. Am J Psychiatry 1989; 146: 558–9PubMed Tondo L, Burrai C, Scamonatti L, et al. Carbamazepine in panic disorder. Am J Psychiatry 1989; 146: 558–9PubMed
90.
go back to reference Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988; 145: 1104–9PubMed Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988; 145: 1104–9PubMed
91.
go back to reference McNamara ME, Fogel BS. Anticonvulsant-responsive panic attacks with temporal lobe EEG abnormalities. J Neuropsychiatry Clin Neurosci 1990; 2: 193–6PubMed McNamara ME, Fogel BS. Anticonvulsant-responsive panic attacks with temporal lobe EEG abnormalities. J Neuropsychiatry Clin Neurosci 1990; 2: 193–6PubMed
92.
go back to reference Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002; 63 Suppl. 14: 9–16PubMed Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002; 63 Suppl. 14: 9–16PubMed
93.
go back to reference Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50(11): 884–95PubMed Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50(11): 884–95PubMed
94.
go back to reference Strand M, Hetta J, Rosen A, et al. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990; 51 Suppl.: 40–5PubMed Strand M, Hetta J, Rosen A, et al. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990; 51 Suppl.: 40–5PubMed
95.
go back to reference Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62(5): 350–7PubMed Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62(5): 350–7PubMed
96.
go back to reference Rynn MA, Siwueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158(12): 2008–14PubMed Rynn MA, Siwueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158(12): 2008–14PubMed
97.
go back to reference Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry 1999; 60 Suppl. 1: 2–19 Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry 1999; 60 Suppl. 1: 2–19
98.
go back to reference Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157(6): 968–74PubMed Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157(6): 968–74PubMed
99.
go back to reference Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160(3): 533–40PubMed Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160(3): 533–40PubMed
100.
go back to reference Lydiard B, Bielski RJ, Zornberg GL, et al. Efficacy of pregabalin in treating psychic and somatic symptoms in generalized anxiety disorder (GAD) [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco Lydiard B, Bielski RJ, Zornberg GL, et al. Efficacy of pregabalin in treating psychic and somatic symptoms in generalized anxiety disorder (GAD) [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco
101.
go back to reference Montgomery SA, Rickels K, Belski RJ, et al. Pregabalin in generalized anxiety disorder: speed of onset [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco Montgomery SA, Rickels K, Belski RJ, et al. Pregabalin in generalized anxiety disorder: speed of onset [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco
102.
go back to reference Pollack MH, Zimbroff DL, Tobia K, et al. Pregabalin in generalized anxiety disorder: analyses of subsyndromic depression [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco Pollack MH, Zimbroff DL, Tobia K, et al. Pregabalin in generalized anxiety disorder: analyses of subsyndromic depression [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco
103.
go back to reference Papp LA, Ray S. Tiagabine treatment of generalized anxiety disorder [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco Papp LA, Ray S. Tiagabine treatment of generalized anxiety disorder [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco
104.
go back to reference Rosenthal MH, Dolnak D. Tiagabine for the treatment of generalized anxiety disorder [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco Rosenthal MH, Dolnak D. Tiagabine for the treatment of generalized anxiety disorder [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco
105.
go back to reference Van Ameringen M, Pollack MH, Roy-Byrne. A randomized, double-blind, placebo-controlled study of tiagabine in patients with generalized anxiety disorder [poster]. 24th Collegium Internationale Neuro-Psychopharmacologicium (CINP) Congress; 2004 Jun 20–24; Paris Van Ameringen M, Pollack MH, Roy-Byrne. A randomized, double-blind, placebo-controlled study of tiagabine in patients with generalized anxiety disorder [poster]. 24th Collegium Internationale Neuro-Psychopharmacologicium (CINP) Congress; 2004 Jun 20–24; Paris
106.
go back to reference Pollack M. Levetiractam (Keppra) for anxiety. Curbside Consultant 2002; 1(4): 4 Pollack M. Levetiractam (Keppra) for anxiety. Curbside Consultant 2002; 1(4): 4
107.
go back to reference Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder: OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169(4): 468–74PubMed Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder: OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169(4): 468–74PubMed
108.
go back to reference Tllefson GD, Rampey Jr AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51(7): 559–67 Tllefson GD, Rampey Jr AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51(7): 559–67
109.
go back to reference Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20mg, 40mg, and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16(2): 75–86PubMed Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20mg, 40mg, and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16(2): 75–86PubMed
110.
go back to reference Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996; 11(1): 21–9PubMed Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996; 11(1): 21–9PubMed
111.
go back to reference Kronig MH, Apter J, Asnis G, et al. Placebo-controlled, multicenter study of sertraline treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1999; 19(2): 172–6PubMed Kronig MH, Apter J, Asnis G, et al. Placebo-controlled, multicenter study of sertraline treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1999; 19(2): 172–6PubMed
112.
go back to reference Clomipramine Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 730–8 Clomipramine Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 730–8
113.
go back to reference Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992; 161: 665–70PubMed Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992; 161: 665–70PubMed
114.
go back to reference McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302–8PubMed McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302–8PubMed
115.
go back to reference Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000; 10(3): 165–9PubMed Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000; 10(3): 165–9PubMed
116.
go back to reference McDougle CJ, Epperson CN, Peolton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794–801PubMed McDougle CJ, Epperson CN, Peolton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794–801PubMed
117.
go back to reference Cora-Locatelli G, Greenberg BD, Martin J, et al. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. J Clin Psychiatry 1998; 59(9): 480–1PubMed Cora-Locatelli G, Greenberg BD, Martin J, et al. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. J Clin Psychiatry 1998; 59(9): 480–1PubMed
118.
go back to reference Cora-Locatelli G, Greenberg BD, Martin J, et al. Rebound psychiatric and physical symptoms after gabapentin discontinuation [letter]. J Clin Psychiatry 1998; 59(3): 131PubMed Cora-Locatelli G, Greenberg BD, Martin J, et al. Rebound psychiatric and physical symptoms after gabapentin discontinuation [letter]. J Clin Psychiatry 1998; 59(3): 131PubMed
119.
go back to reference Deltito JA. Valproate pretreatment for the difficult-to-treat patient with OCD [letter]. J Clin Psychiatry 1994; 55(11): 500PubMed Deltito JA. Valproate pretreatment for the difficult-to-treat patient with OCD [letter]. J Clin Psychiatry 1994; 55(11): 500PubMed
120.
go back to reference Cora-Locatelli G, Greenberg BD, Martin JD, et al. Valproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry 1998; 59: 82PubMed Cora-Locatelli G, Greenberg BD, Martin JD, et al. Valproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry 1998; 59: 82PubMed
121.
go back to reference Iwata Y, Kotani Y, Hoshino R, et al. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry 2000; 61(7): 528–9PubMed Iwata Y, Kotani Y, Hoshino R, et al. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry 2000; 61(7): 528–9PubMed
122.
go back to reference Jenike MA, Brotman AW. The EEG in obsessive-compulsive disorder. J Clin Psychiatry 1984; 45: 122–4PubMed Jenike MA, Brotman AW. The EEG in obsessive-compulsive disorder. J Clin Psychiatry 1984; 45: 122–4PubMed
123.
go back to reference Joffe RT, Swinson RP. Carbamazepine in obsessive-compulsive disorder. Biol Psychiatry 1987; 22(9): 1169–71PubMed Joffe RT, Swinson RP. Carbamazepine in obsessive-compulsive disorder. Biol Psychiatry 1987; 22(9): 1169–71PubMed
124.
go back to reference Van Ameringen M, Mancini C, Pipe B, et al. Adjunctive topiramate in treatment resistant obsessive compulsive disorder [poster]. 157th Annual Meeting of the American Psychiatric Association (APA); 2004 May 1–6; New York Van Ameringen M, Mancini C, Pipe B, et al. Adjunctive topiramate in treatment resistant obsessive compulsive disorder [poster]. 157th Annual Meeting of the American Psychiatric Association (APA); 2004 May 1–6; New York
125.
go back to reference Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 2000; 34: 527–8PubMed Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 2000; 34: 527–8PubMed
126.
go back to reference Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60(4): 392–400PubMed Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60(4): 392–400PubMed
127.
go back to reference Crane DL. The selective GABA reuptake inhibitor tiagabine for the treatment of anxiety [poster]. 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21–24; Austin Crane DL. The selective GABA reuptake inhibitor tiagabine for the treatment of anxiety [poster]. 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21–24; Austin
128.
go back to reference Schwartz TL, Ashar N, Husain J, et al. Open-label study of tiagabine augmentation therapy for anxiety disorders [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco Schwartz TL, Ashar N, Husain J, et al. Open-label study of tiagabine augmentation therapy for anxiety disorders [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco
129.
go back to reference Taylor F. Tiagabine for the treatment of posttraumatic stress disorder [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco Taylor F. Tiagabine for the treatment of posttraumatic stress disorder [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco
130.
go back to reference Kennedy SH, Lam RW, Cohen N, et al. Clinical guidelines for the treatment of depressive disorders: IV. Medication and other biological treatments. Can J Psychiatry 2001; 46 Suppl. 1: 38S–58SPubMed Kennedy SH, Lam RW, Cohen N, et al. Clinical guidelines for the treatment of depressive disorders: IV. Medication and other biological treatments. Can J Psychiatry 2001; 46 Suppl. 1: 38S–58SPubMed
Metadata
Title
Antiepileptic Drugs in the Treatment of Anxiety Disorders
Role in Therapy
Authors
Dr Michael Van Ameringen
Catherine Mancini
Beth Pipe
Mark Bennett
Publication date
01-10-2004
Publisher
Springer International Publishing
Published in
Drugs / Issue 19/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200464190-00004

Other articles of this Issue 19/2004

Drugs 19/2004 Go to the issue

Adis Drug Profile

Lumiracoxib

Guest Commentary

Prulifloxacin

Guest Commentary

Lumiracoxib

Adis Drug Profile

Anidulafungin